China Medical System Holdings Limited won the award of Golden Hong Kong Stocks “The best Hong Kong stock connect company”

Company News

As the new year begins with fresh updates, the fourth “Golden Hong Kong stocks annual awards ceremony” grandly opened at Shenzhen Futian Hilton. China Medical System Holdings Limited, a global innovation-driven specialty pharmaceutical company focusing on Chinese market, won the award of “The best Hong Kong stock connect company”on the strength of its steady historical performance and concept of innovation-driven development.

The “Golden Hong Kong stock annual awards ceremony” is jointly sponsored by China leading Hong Kong stock information platform- Zhitong finance and Tonghuashun finance, and co organized by the Roadshowing. “The best Hong Kong stock connect company” aims to commend the listed Hong Kong companies which possess healthy corporate governance structure, significant industry position, good main business and capabilities to provide investors with sustained and stable value return. The award of “The best Hong Kong stock connect company” highlights the attention of the industry and investors to the company. It is a great encouragement and also an incentive for China Medical System Holdings Limited.

In the past year, China’s pharmaceutical industry continually accelerated structural upgrading under the guidance of numerous policies. With a forward-looking strategic vision, China Medical System adhered to its product deployment strategy with innovative products as the core. The Group mainly did equity investments in overseas R&D companies or established long-term strategic cooperation with global leading pharmaceutical companies, making arrangement of  innovative products in different R&D fields multi-dimensionally. In 2019, to speed up the pace of innovative products to launch in China market, the group increased the number of overseas listed innovative products. The group firmly believes that the soul of a pharmaceutical company for its survival and development is its products. A product portfolio with differentiated competitive advantages is the most important strength for the Group to become a global innovative specialty pharmaceutical company. The Group is confident to constantly launch innovative products to strength its core competitive advantage, ensuring that the the innovative products can be launched to the market successively in short-, mid- and long-term to meet the unmet medical needs of Chinese market.

The development of China Medical System Holdings Limited is accompanied by the attention and support from investors. The Group is deeply grateful to domestic and foreign investors and analysts for their support all the time, and will continually maintain the tie to the capital market with a sincere attitude of communication, gathering to witness the glory of the company development!